GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Ending Cash Position

TELA Bio (TELA Bio) Ending Cash Position : $46.99 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Ending Cash Position?

TELA Bio's Ending Cash Position for the quarter that ended in Dec. 2023 was $46.99 Mil.

TELA Bio's quarterly Ending Cash Position declined from Jun. 2023 ($65.27 Mil) to Sep. 2023 ($58.20 Mil) and declined from Sep. 2023 ($58.20 Mil) to Dec. 2023 ($46.99 Mil).

TELA Bio's annual Ending Cash Position declined from Dec. 2021 ($43.93 Mil) to Dec. 2022 ($42.02 Mil) but then increased from Dec. 2022 ($42.02 Mil) to Dec. 2023 ($46.99 Mil).


TELA Bio Ending Cash Position Historical Data

The historical data trend for TELA Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Ending Cash Position Chart

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 45.30 74.39 43.93 42.02 46.99

TELA Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.02 30.12 65.27 58.20 46.99

TELA Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TELA Bio's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=42.019+4.975
=46.99

TELA Bio's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=58.202+-11.208
=46.99


TELA Bio Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TELA Bio's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


TELA Bio (TELA Bio) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Executives
Gregory A. Firestone officer: Chief Business Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca officer: COO and CFO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish director, officer: Chief Executive Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p. other: See footnotes 1 and 2 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp 10 percent owner QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p. 10 percent owner CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran director 0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans director 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355

TELA Bio (TELA Bio) Headlines

From GuruFocus

TELA Bio Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 04-19-2023

TELA Bio to Announce First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-27-2023

TELA Bio Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023

TELA Bio Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 04-18-2023